CN1290525A - Freeze dried zhalaipulong instant oral composition - Google Patents
Freeze dried zhalaipulong instant oral composition Download PDFInfo
- Publication number
- CN1290525A CN1290525A CN 00129669 CN00129669A CN1290525A CN 1290525 A CN1290525 A CN 1290525A CN 00129669 CN00129669 CN 00129669 CN 00129669 A CN00129669 A CN 00129669A CN 1290525 A CN1290525 A CN 1290525A
- Authority
- CN
- China
- Prior art keywords
- zaleplon
- compositions
- composition
- oral
- instant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims description 51
- 150000003839 salts Chemical class 0.000 claims abstract 2
- HUNXMJYCHXQEGX-UHFFFAOYSA-N zaleplon Chemical compound CCN(C(C)=O)C1=CC=CC(C=2N3N=CC(=C3N=CC=2)C#N)=C1 HUNXMJYCHXQEGX-UHFFFAOYSA-N 0.000 claims description 32
- 229960004010 zaleplon Drugs 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 12
- 239000000796 flavoring agent Substances 0.000 claims description 10
- 235000013355 food flavoring agent Nutrition 0.000 claims description 9
- 108010010803 Gelatin Proteins 0.000 claims description 8
- 229920000159 gelatin Polymers 0.000 claims description 8
- 239000008273 gelatin Substances 0.000 claims description 8
- 235000019322 gelatine Nutrition 0.000 claims description 8
- 235000011852 gelatine desserts Nutrition 0.000 claims description 8
- 239000004094 surface-active agent Substances 0.000 claims description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
- 229930195725 Mannitol Natural products 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 239000000594 mannitol Substances 0.000 claims description 6
- 235000010355 mannitol Nutrition 0.000 claims description 6
- 239000000375 suspending agent Substances 0.000 claims description 5
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 206010022437 insomnia Diseases 0.000 claims description 3
- 241001597008 Nomeidae Species 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 14
- 239000002131 composite material Substances 0.000 abstract 3
- 239000012453 solvate Substances 0.000 abstract 1
- 239000000725 suspension Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 238000004108 freeze drying Methods 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 238000001035 drying Methods 0.000 description 5
- HVUMOYIDDBPOLL-UHFFFAOYSA-N 2-(3,4-Dihydroxyoxolan-2-yl)-2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)C1OCC(O)C1O HVUMOYIDDBPOLL-UHFFFAOYSA-N 0.000 description 4
- 108010011485 Aspartame Proteins 0.000 description 4
- 239000000605 aspartame Substances 0.000 description 4
- 235000010357 aspartame Nutrition 0.000 description 4
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 4
- 229960003438 aspartame Drugs 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 230000000147 hypnotic effect Effects 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 210000003238 esophagus Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 239000005030 aluminium foil Substances 0.000 description 2
- 239000007958 cherry flavor Substances 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 229940068682 chewable tablet Drugs 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229940023488 pill Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000000859 sublimation Methods 0.000 description 2
- 230000008022 sublimation Effects 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 240000006413 Prunus persica var. persica Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical group OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000009748 deglutition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000517 effect on sleep Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 230000007775 late Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003597 spicing agent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a freeze dried composite which may be taken orally and can be dissolved in mouth fast. The composite contains Zhalaipulong or its medicinally acceptable solvate and salt and one or more kinds of medicinally acceptable supplementary material. The present invention also describes the preparation process and clinical application of the composite.
Description
The present invention relates to a kind of pharmaceutical composition, a kind of specifically oral instant pharmaceutical composition that supplies that uses the Freeze Drying Technique preparation.The effective ingredient that said composition comprises is N-[3-(3-cyano pyrazole [1, a 5-a] pyrimidin-7-yl) phenyl]-N-ethyl-ethamine, general Zaleplon by name.This structural formula of compound can be expressed from the next:
Zaleplon structure involved in the present invention is different from traditional hypnotic (benzene diaza class, barbiturates and known other hypnotic), it is the short-acting hypnotic of a kind of BZ1 of acting on (ω 1) receptor, it optionally acts on the ω site of benzene phenodiazine in the brain-GABA receptor complex a subunit, thus performance sleep effect.Its human body half-life is 1 hour only, and the back metabolism rapidly of taking medicine replaces normal natural sleep, has therefore farthest eliminated late effect next day that hypnotic often had.Test shows, takes Zaleplon and withdraws no withdrawal symptoms after 12 months, shows patient's no dependence, interrupts taking the bounce-back that Zaleplon 4 Zhou Houwei cause insomnia.Compare at present clinical employed most of sleeping pill selectivitys with it relatively poor or metabolism is slower, and show clinical withdrawal symptoms.
In Europe, the U.S. and Canada surpass 3700 routine patients' (comprise 65-85 year gerontal patient) clinical trial certificate: Zaleplon is helping the patient to keep the natural sleep state aspect evident in efficacy.
Find under study for action, although various traditional oral Pharmaceutical dosage forms such as existence such as tablet, capsule and pill are arranged, but these Orally administered composition forms have shortcoming separately, especially concerning the gerontal patient and can not swallow or the patient that is reluctant to swallow, the consideration of dosage form design is still insufficient.With regard to traditional tablet and capsule, the more weak patient of gerontal patient or swallow complaint is difficult to swallow or often produces the sensation in " being stuck in " throat and cause discomfort, and these compositionss pass through the process of disintegrate and stripping in vivo mostly, and general onset is slower.Need not in powder and the granule body through disintegrating procedue, but its mouthfeel is bad, takes inconvenience, and unrestrained easily and cause dosage inaccurate when unpacking.Taking these oral solid formulations in addition needs great quantity of water drinking, and (before sleeping) then can cause patient's compliance to descend under should not the great quantity of water drinking environment.Liquid oral compositions such as syrup etc. are easy to take relatively, but can not expect then that for most of gerontal patients being difficult to measure volume required patient can take by correct dosage.Therefore society wishes to have taking convenience very much, and onset is rapid, acts on stable pharmaceutical composition.
The problems referred to above that appear as of using the oral instant compositions of freeze-drying method preparation provide a solution.For example Chinese patent NO 1140408,1085081,1140407; Described in British patent NO 1548022,2111423,2119246,2114440,2111184,2120370 and the United States Patent (USP) NO 5046618,5188825, list herein and briefly introduce.
The end of the seventies, Britain Weyth company at first is applied in the Freeze Drying Technique of injection on the oral formulations, oral freeze-dried compositions begins one's study, the eighties, Xie Le company participated in exploitation, the efficient suitability for industrialized production of primary study has the freeze-dried composition of a plurality of medicines to apply for a patent or produce listing at present.
Oral freeze-dried compositions is to adopt vacuum freezing drying method production, and generally included for three steps: 1 freezes: medicinal liquid is placed mould, be refrigerated to fully solidify, molding; 2 sublimation dryings: moisture is separated with solute with methods such as decompression, intensifications; 3 packings.
Oral instant can dissolve rapidly in 5-15s in the oral cavity and not need the water assisting deglutition, only can finish with several swallowing acts and take medicine, very convenient.What oral formulations was removed situation in clinostatism volunteer esophagus comparison shows that ordinary tablet and capsule move slower in esophagus, oral instant and is not had trapping phenomena then owing to can collapse the dissolving of loosing rapidly in esophagus, so more convenient practicality.
In animal body and the test of oral instant of carrying out in the human body pharmacokinetics also show, oral instant absorb than ordinary tablet fast, the blood drug level height, bioavailability is good, can reduce dosage.It is big that the oral fast solubility preparation has also overcome the suppository absorption difference, though injection absorbs the shortcoming of fast administration inconvenience, it absorbs fast, and taking convenience and onset are rapid.
In addition, γ-flicker labelling method is to oral instant, chewable tablet and liquid preparation show that in gastric retention time mucosal coating The Characteristic Study oral instant retention time at gastric obviously is longer than conventional tablet and liquid preparation, and be also even than chewable tablet in the distribution of gastric mucosa.
In the process of the oral instant compositions of the cryodesiccated Zaleplon of research, we find, Zaleplon is different with other drug, it is difficult in the water and disperses, and dispersion is very unstable, and the divided dose of well-known oral freeze-dried instant oral composition is based on the volume of inserting the mould herb liquid or quality, and the instability of Zaleplon dispersion directly can influence the amount of the every contained Zaleplon of finished product.
We find to adopt following several mode to address this problem now: the micronized Zaleplon of 1 employing is a raw material; 2 add the surfactant of proper proportion; 3 add the stability that suspending agent can further improve disperse system.
Therefore the present invention at first provides a kind of for oral instant freeze-dried composition, and said composition comprises Zaleplon or the receptible derivant of its medicine, one or more surfactants, one or more suspending agents.
Term " instant " is meant according to disclosed method among the British patent No1548022, and be 60 seconds or shorter the disintegration of solid dosage forms in 37 ℃ of water, preferred 5-10 second or shorter time.
As described in above-mentioned patent, owing to said composition need exist with solid form, and should guarantee its mouldability, be beneficial to the production and the packing of product; The existence of framework material has simultaneously guaranteed the porous status spongiosus of instant compositions, can rapid osmotic compositions be dissolved rapidly when making water touch instant compositions, so said composition can comprise the skeletal substance of the acceptable water miscible or water dispersible of a series of medicines to compositions inside.Suitable framework material comprises, the mixture of gelatin (gelatin that comprises partial hydrolysis), polysaccharide or gelatin polysaccharide, preferably gelatin hydrolysate.
For keeping said composition hardness, said composition can comprise suitable filler, suitable filler comprises preferably polyhydric alcohol of polyhydric alcohol (as mannitol, sorbitol and xylitol etc.) sugar (sucrose, glucose, lactose and maltose etc.), because of its compositions has preferably mouthfeel and has better physical character.
Though Zaleplon is water-soluble hardly, still need add an amount of flavoring agent and cover its bitter taste, available flavoring agent can comprise spicing agent (as Fructus Fragariae Ananssae, Herba Menthae, Fructus Pruni pseudocerasi, peach flavor essence etc.); The mixture of sweet taste flavoring agent (as aspartame etc.) and other flavoring agents (as citric acid etc.) or several flavoring agents.
The oral instant compositions of the cryodesiccated Zaleplon of the present invention adopts the classical way preparation described in the above-mentioned patent.
The oral freeze-dried compositions of Zaleplon is to adopt vacuum freezing drying method production, comprises for four steps altogether: the preparation of 1 suspension: micronized Zaleplon is added surfactant and disperse medium an amount of, smash to pieces and be uniformly dispersed; 2 freeze: with the Zaleplon dispersion liquid by volume divided dose place mould, be refrigerated to fully rapidly solidify, molding; 3 sublimation dryings are removed moisture to being lower than 5%; 4 press molds packing.
In preparation suspension process, the suspension solution of Zaleplon is extremely unstable and make final product medicament contg inequality, and the method that the present invention relates to can address this problem.
During drug suspension, the option table surface-active agent adds in the solvent for use in preparation, the method that adopts tissue to smash to pieces, and homodisperse, thereby guaranteed the homogeneity of unit dose Chinese medicine content.The surfactant that is suitable for can comprise tween, span and poloxamer and composition thereof.Preferred surfactants is the mixture of Tween 80 and sorbester p18 (1: 1).
Production cycle is longer, adds the stability that suspending agent can further increase suspension, and suitable suspending agent can comprise polyvinylpyrrolidone, cellulose family, carbomer or their mixture, preferably polyvinylpyrrolidone.
The present invention relates to the mold volumes size and take from the size and the shape of Zaleplon tablet.The WO94/12142 suggestion has provided the preferred mold materials of mold, and we adopt preferred blister pack bag.With automatic filling means the required dosage suspension is inserted mold.
The present invention prepares the oral instant compositions of Zaleplon with freeze-drying.In freeze drying chamber, decompression down makes Zaleplon suspension solution coagulation forming in the mould with freeze-drying, removes moisture, under the 0.1-1.0 millibar dry 180-500 minute.
Packaging material the present invention adopts pressure sensitive adhesion cover material on the mold materials around the depression, preferred aluminium foil of coverage rate or lamination aluminium foil.Covering mould can be adhered on the mold materials by the same manner.
Be used to form the solvent preferred water of pharmaceutically active substance suspension, also can sneak into cosolvent such as ethanol if desired.
The suspension that the present invention relates to has also comprised supplementary elements such as preservative agent, flavoring agent, coloring agent, sweeting agent, filler and composition thereof.Used preservative agent is a benzoate, and flavoring agent is the Fructus Pruni pseudocerasi flavoring agent, and selected sweeting agent is an aspartame, and filler is a mannitol.These usual excipients can be improved the physical property of peroral dosage form.
The oral instant compositions of cryodesiccated Zaleplon provided by the invention, the content of its Zaleplon is between 1mg-20mg.
The invention provides a kind of method for the treatment of human insomnia disease, this method comprises the oral instant compositions of Zaleplon of taking a kind of freeze-drying method preparation to the patient.
Following non-limiting example will the present invention will be further described.
Embodiment 1:
Zaleplon 5.0mg
(mean diameter is less than 50 μ m)
Gelatin 5.5mg
Mannitol 4.1mg
Aspartame 0.75mg
Cherry flavor 0.30mg
Tween 80 0.50mg
Sorbester p18 0.50mg
Pure water adds to 0.3ml
This compositions can adopt following method preparation.
1 adds gelatin in the entry and to soak dissolving, adds the Tween 80 sorbester p18 and is stirred to dissolving, adds Zaleplon and disperses with refiner, adds other adjuvant mix homogeneously.
2 with the suspension divided dose in blister pack.
3 freezing drying under reduced pressure to moisture less than 5%.
4 press molds packing.
1 suspension of writing out a prescription has obvious layering after 1 hour in placing, and requires to place mould and quick freezing molding at once after the preparation, to prevent the layering of Zaleplon suspension.
Embodiment 2:
Zaleplon 5.0mg
Gelatin 5.5mg
Mannitol 4.1mg
Polyvinylpyrrolidone 2.6mg
Aspartame 0.75mg
Cherry flavor 0.30mg
Tween 80 0.50mg
Sorbester p18 0.50mg
Pure water adds to 0.3ml
Preparation method is with prescription 1.
Prescription 2 increases polyvinylpyrrolidone on prescription 1 basis makes the Zaleplon suspension stable in 6 hours, is more suitable for suitability for industrialized production.
Claims (8)
1. one kind can supply oral instant freeze-dried composition, and said composition comprises Zaleplon or the receptible derivant of its medicine, one or more surfactants, the receptible excipient of one or more medicines.
2. the compositions of claim 1, said composition contains one or more suspending agents.
3. claim 1 or 2 compositions, the said composition outward appearance is a tablet.
4. the compositions of claim 1-3, said composition comprises into the Zaleplon of salt form.
5. the compositions of any one requirement among the claim 1-4, wherein sweeting agent comprises mannitol.
6. the compositions of any one requirement among the claim 1-4, wherein the content of Zaleplon is 1mg-50mg.
7. the compositions of any one claim among the claim 1-6, said composition comprises Zaleplon, gelatin, mannitol, flavoring agent.
8. the method for a Cure for insomnia, this method comprises the compositions of using any one claim among the claim 1-7 to the patient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00129669 CN1290525A (en) | 2000-10-10 | 2000-10-10 | Freeze dried zhalaipulong instant oral composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00129669 CN1290525A (en) | 2000-10-10 | 2000-10-10 | Freeze dried zhalaipulong instant oral composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1290525A true CN1290525A (en) | 2001-04-11 |
Family
ID=4593661
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 00129669 Pending CN1290525A (en) | 2000-10-10 | 2000-10-10 | Freeze dried zhalaipulong instant oral composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1290525A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101396364B (en) * | 2007-09-27 | 2011-10-26 | 北京天川军威医药技术开发有限公司 | Zaleplon oral-cavity administration system or composition and preparation method thereof |
| CN102631289A (en) * | 2004-10-28 | 2012-08-15 | 潘特克股份公司 | A highly porous, fast-disintegrating solid dosage form and its way of manufacturing comprising the preparation of a podwer and a freezedrying step |
| US8454996B2 (en) | 1998-09-24 | 2013-06-04 | Orexo Ab | Pharmaceutical composition for the treatment of acute disorders |
| US9265720B2 (en) | 2004-10-27 | 2016-02-23 | Orexo Ab | Pharmaceutical formulations useful in the treatment of insomnia |
-
2000
- 2000-10-10 CN CN 00129669 patent/CN1290525A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8454996B2 (en) | 1998-09-24 | 2013-06-04 | Orexo Ab | Pharmaceutical composition for the treatment of acute disorders |
| US8512747B2 (en) | 1998-09-24 | 2013-08-20 | Orexo Ab | Pharmaceutical composition for the treatment of acute disorders |
| US9265720B2 (en) | 2004-10-27 | 2016-02-23 | Orexo Ab | Pharmaceutical formulations useful in the treatment of insomnia |
| US9597281B2 (en) | 2004-10-27 | 2017-03-21 | Orexo Ab | Pharmaceutical formulations useful in the treatment of insomnia |
| CN102631289A (en) * | 2004-10-28 | 2012-08-15 | 潘特克股份公司 | A highly porous, fast-disintegrating solid dosage form and its way of manufacturing comprising the preparation of a podwer and a freezedrying step |
| CN101396364B (en) * | 2007-09-27 | 2011-10-26 | 北京天川军威医药技术开发有限公司 | Zaleplon oral-cavity administration system or composition and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6455053B1 (en) | Quickly soluble solid preparations | |
| CN1123142A (en) | Fluoxetine pharmaceutical formulations | |
| CN1473562A (en) | Mouth cavity quick dissolving quick disintegrating freeze-dried tablet and its preparing method | |
| AU702161B2 (en) | Pharmaceutical compositions comprising monoamine oxidase B inhibitors | |
| Khanna et al. | Fast dissolving tablets-A novel approach | |
| EP3641773A1 (en) | Gelatin gummy compostion and methods of making and using thereof | |
| WO2013123623A1 (en) | Oroally disintegrating tablet and preparation method therefor | |
| HUT74514A (en) | Rapidly dissolving oral dosage form | |
| CN101065105A (en) | Rapidly disintegrating solid dosage form with high porosity and its preparation method including steps of producing powder and freeze-drying | |
| Tambe | Mouth dissolving tablets: An overview of formulation technology | |
| CN101301318A (en) | Ginkgo leaf extract oral freeze-dried slices and preparation thereof | |
| CN1631371A (en) | Oral administered bitter free powder of macrolide antibiotic, its prescription and preparation process | |
| CN1214784C (en) | Quick-releasing talbet in vagina and its preparing method | |
| CN103494792B (en) | Compound phloroglucinol freeze-dried orally-disintegrating tablet and preparation method | |
| US20060240101A1 (en) | Orally disintegrating pharmaceutical tablet formulations of olanzapine | |
| Singh et al. | A review on fast dissolving tablets (FDTs) | |
| CN101401796A (en) | Pramipexole orally disintegrating tablets and preparation method thereof | |
| JPH0739350B2 (en) | Herbal medicine chewable tablets | |
| Nasreen et al. | Mouth dissolving tablets-A unique dosage form curtailed for special purpose: a review | |
| CN102525972A (en) | Calcium-ion antagonist orally disintegrating tablet and preparation method thereof | |
| CN101023948A (en) | Rimonabant and cyclodextrin inclusion compound of its salt capable of being as medicine, its preparing method and medicine use | |
| JPH11116465A (en) | Rapid dissolving preparation and method for producing the same | |
| JP4196417B2 (en) | Intraoral rapidly disintegrating tablet and method for producing the same | |
| CN1559424A (en) | Breviscapine dry suspension | |
| CN1742743A (en) | Pseudo-ginseng saponin oral disintegration tablet and preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Wanquan Sunlight Medicine Science and Technology Co., Ltd., Beijing Document name: Notice of first review |
|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Wanquan Sunlight Medicine Science and Technology Co., Ltd., Beijing Document name: Deemed as a notice of withdrawal |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |